NASDAQ:NITE - Nightstar Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.34 +1.46 (+9.81 %)
(As of 06/25/2018 01:55 PM ET)
Previous Close$15.15
Today's Range$15.15 - $16.34
52-Week Range$10.01 - $24.93
Volume600 shs
Average Volume45,261 shs
Market Capitalization$418.13 million
P/E Ratio-9.13
Dividend YieldN/A
BetaN/A
Nightstar Therapeutics logoNightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Receive NITE News and Ratings via Email

Sign-up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NITE
CUSIPN/A
Phone646-522-8445

Debt

Debt-to-Equity RatioN/A
Current Ratio12.69
Quick Ratio12.69

Price-To-Earnings

Trailing P/E Ratio-9.13
Forward P/E Ratio-8.42
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.48 per share
Price / Book3.65

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees23
Outstanding Shares28,100,000

The Truth About Cryptocurrencies

Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions

What is Nightstar Therapeutics' stock symbol?

Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."

How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) released its quarterly earnings data on Wednesday, June, 6th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.12. View Nightstar Therapeutics' Earnings History.

When is Nightstar Therapeutics' next earnings date?

Nightstar Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, September, 5th 2018. View Earnings Estimates for Nightstar Therapeutics.

What price target have analysts set for NITE?

6 brokers have issued 12-month price objectives for Nightstar Therapeutics' shares. Their predictions range from $20.00 to $40.00. On average, they anticipate Nightstar Therapeutics' stock price to reach $28.50 in the next twelve months. View Analyst Ratings for Nightstar Therapeutics.

What are Wall Street analysts saying about Nightstar Therapeutics stock?

Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
  • 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (6/6/2018)
  • 2. Mizuho analysts commented, "We’ve included links to the various abstracts below along with our thoughts on some of the abstracts ahead of the conference." (4/27/2018)

Who are some of Nightstar Therapeutics' key competitors?

Who are Nightstar Therapeutics' key executives?

Nightstar Therapeutics' management team includes the folowing people:
  • Mr. David Fellows, CEO & Director (Age 61)
  • Mr. Senthil Sundaram, CFO & Principal Accounting Officer (Age 40)
  • Dr. Gregory Robinson Ph.D., Chief Scientific Officer (Age 59)
  • Mr. Aniz Girach, Chief Medical Officer
  • Dr. Tuyen Ong M.D., MRCOphth, MBA, Exec. VP & Chief Devel. Officer (Age 43)

When did Nightstar Therapeutics IPO?

(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

Has Nightstar Therapeutics been receiving favorable news coverage?

Media coverage about NITE stock has trended somewhat negative on Monday, Accern reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nightstar Therapeutics earned a news sentiment score of -0.07 on Accern's scale. They also gave media coverage about the company an impact score of 46.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Nightstar Therapeutics' major shareholders?

Nightstar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (6.30%), Franklin Resources Inc. (0.49%) and Millennium Management LLC (0.13%). View Institutional Ownership Trends for Nightstar Therapeutics.

Which major investors are selling Nightstar Therapeutics stock?

NITE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc. and Redmile Group LLC. View Insider Buying and Selling for Nightstar Therapeutics.

Which major investors are buying Nightstar Therapeutics stock?

NITE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Nightstar Therapeutics.

How do I buy shares of Nightstar Therapeutics?

Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nightstar Therapeutics' stock price today?

One share of NITE stock can currently be purchased for approximately $15.90.

How big of a company is Nightstar Therapeutics?

Nightstar Therapeutics has a market capitalization of $418.13 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe.

How can I contact Nightstar Therapeutics?

Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected]


MarketBeat Community Rating for Nightstar Therapeutics (NITE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.